Gynecology & Obstetrics in Massachusetts

Tegra Medical is a global contract manufacturer specializing in end-to-end production of medical devices. Headquartered in Franklin, Massachusetts, with manufacturing facilities across the United States, Costa Rica, Switzerland, and Asia, the company employs over 1,000 people. Tegra Medical delivers comprehensive manufacturing solutions including design, prototyping, precision production, assembly, packaging, and sterilization for complex metal and plastic components. The company serves multiple therapeutic areas including oncology, orthopedics, cardiology, minimally invasive surgery, ophthalmic, women's health, drug delivery, and robotic-assisted surgery applications. Advanced manufacturing capabilities include Swiss machining, multi-axis milling, injection molding, wire grinding, and precision finishing. Tegra Medical maintains ISO 13485 certification and FDA registration, supported by rigorous quality management systems. The company also operates Quick Wire & Tubing, an e-commerce platform offering in-stock and custom wire, tubing, and secondary processing services for medical device development and prototyping.

SwimEx, Inc. is a Massachusetts-based manufacturer of custom-designed aquatic therapy and rehabilitation pools founded in 1986. The company specializes in resistance pools featuring patented paddlewheel water current technology for therapeutic and athletic training applications. SwimEx serves hospitals, rehabilitation clinics, senior living facilities, veterinary practices, athletic teams, sports institutions, spas, wellness centers, and residential customers worldwide. Their commercial-grade fiberglass pools are engineered for durability and low maintenance, offering adjustable water flow for full-body fitness, injury recovery, balance improvement, and neurological rehabilitation. The company's DepthSelect™ Series provides adjustable treadmill zone depth to support staged rehabilitation protocols. SwimEx pools are trusted by professional sports teams (Philadelphia Eagles, New England Patriots, Utah Jazz), universities, and healthcare institutions for both performance training and therapeutic recovery programs.

KARL STORZ is a global medical technology manufacturer specializing in endoscopic visualization systems, minimally invasive surgical instruments, and operating room integration solutions. The company develops and manufactures rigid and flexible endoscopes, laparoscopic and arthroscopic equipment, video laryngoscopes for airway management, and specialized instruments for general and visceral surgery, urology, otorhinolaryngology, gynecology, and gastroenterology. KARL STORZ offers comprehensive imaging solutions including camera systems, light sources, and monitors designed for integration into surgical workflows. The product portfolio exceeds 15,000 items spanning telescopes, instruments, electrosurgical devices, and OR integration systems. The company serves hospitals, surgical centers, and specialized practices globally. KARL STORZ provides extensive customer support including product manuals, online catalogs, repair and maintenance services, and training programs through dedicated training centers. The company has pioneered video laryngoscope technology and maintains leadership in endoscopic visualization and laparoscopic surgery solutions. All products are manufactured to medical device standards including FDA clearance and international regulatory compliance. The organization partners with leading physicians, universities, and research institutes to identify clinical trends and translate them into innovative surgical solutions.

Alcresta Therapeutics develops enzyme-based products for rare disease patients requiring enteral nutrition. The company specializes in addressing fat malabsorption disorders, particularly exocrine pancreatic insufficiency, in pediatric and adult patients receiving tube feeding at home or in clinical settings. Alcresta's primary product, RELiZORB® cartridge containing iLipase® (immobilized lipase), is a patented microbead enzyme technology designed to mimic pancreatic lipase function and facilitate fat digestion and absorption in enterally fed patients. RELiZORB is indicated for patients with cystic fibrosis, short bowel syndrome, pancreatitis, digestive cancers, and other conditions causing fat malabsorption. The product is the first and only enzyme product formulated for use directly in enteral feeding systems. Alcresta has received FDA clearance, including recent expanded use authorization for neonates and infants (November 2025). The company conducts clinical research to support product efficacy, including Phase 3 exploratory studies and real-world evidence registries demonstrating growth improvements in pediatric patients. Manufacturing capabilities include enzyme immobilization technology and cartridge formulation. Alcresta serves hospital and home care markets, targeting gastroenterology, pediatrics, and rare disease specialties.

Allurion Technologies is a medical device company specializing in non-surgical weight-loss solutions for obesity management. The company's flagship product, the Allurion Balloon, is a swallowable gastric balloon that occupies stomach space to promote satiety and reduce food intake. Clinical evidence demonstrates that patients achieve an average weight loss of 10–15% of total body weight within four months. The Allurion Program combines the procedureless balloon with a comprehensive digital ecosystem featuring the Allurion Virtual Care Suite, an AI-powered mobile app (Coach Iris), connected smart scale, and multidisciplinary support from dieticians, doctors, and behavior change specialists. The program runs for a minimum of six months and emphasizes metabolically healthy weight loss—preserving lean muscle mass while reducing fat. The device is CE-marked and available globally through accredited clinic partners; it is not currently FDA-approved in the United States. Allurion has served over 180,000 patients worldwide and is publicly traded on the NYSE under ticker ALUR.

Darleys Surgical Co. is a surgical instrument manufacturer and supplier specializing in hand-held surgical instruments, dental instruments, and instrument sets for multiple surgical specialties. The company manufactures a comprehensive range of stainless steel surgical instruments including forceps (extracting, artery), retractors, needle holders, curettes, elevators, and specialized cutting instruments. Product lines span general surgery, orthopedic surgery, obstetrics and gynecology, ENT procedures, and orthodontics. The company also produces "TC Instruments" (tungsten carbide), hollowares (surgical basins and trays), and complete surgical instrument sets for specialty procedures including laminectomy, coronary surgery, foot and ankle repair, and obstetrical procedures. Darleys maintains regulatory compliance with FDA, GMP, CE, ISO 13485 (Medical Devices Quality Management), and ISO 9001 (General Quality Management) certifications. The company exhibits at major medical trade shows including Medica (Düsseldorf) and FIME (Orlando). Products are identified by model numbers (DS-prefix) and are marketed globally through a distributor network. The company emphasizes rapid fulfillment and 24/7 customer service.

Fractyl Health is a clinical-stage medical device and gene therapy company developing targeted interventions for obesity and type 2 diabetes by addressing root causes in the duodenum and pancreas. The company's primary platform, Revita®, is an outpatient endoscopic procedure that resurfaces the duodenal lining to target metabolic dysfunction. Revita is currently under investigational use only in the US under Federal law. The company's second platform, Rejuva®, is a one-time gene therapy designed to enable long-term remission of obesity and type 2 diabetes by targeting pancreatic islet cells; this platform is in early development and not yet approved by any regulatory body. Fractyl has reported positive 6-month open-label results from the REVEAL-1 clinical trial demonstrating sustained post-GLP-1 weight maintenance after a single Revita procedure. The company positions its therapies as alternatives to long-term pharmacological management, seeking to break the cycle of chronic disease treatment. Fractyl's approach centers on endoscopic and molecular interventions rather than traditional pharmaceutical or implantable device solutions.

Axena Health is a women's health company focused on non-invasive, clinically proven treatments for pelvic health conditions. The company develops digital health solutions and wearable/biofeedback systems for pelvic floor disorders, including stress urinary incontinence, urge incontinence, overactive bladder, and fecal incontinence. Their flagship product, the Leva Pelvic Health System, is a home-based, supervised digital rehabilitation platform that combines pelvic floor muscle training with real-time biofeedback technology. Axena Health emphasizes evidence-based care, publishing peer-reviewed research and real-world outcome data. The company serves women across the lifespan, including federal healthcare populations (Veterans Health Administration), and operates internationally with feasibility studies in Nigeria. Leadership includes a Chief Medical Officer with extensive healthcare innovation experience. The company is committed to addressing long-neglected gaps in women's pelvic health research and clinical practice through data-driven, technology-enabled solutions that support the clinician-patient partnership.

Spectrum Fertility Genomics is a leading provider of cutting-edge solutions for In Vitro Fertilization (IVF) and reproductive genomics. The company specializes in epigenomic innovation and genetic analysis tools designed to support fertility clinics, reproductive laboratories, and healthcare professionals. Their product portfolio includes preimplantation genetic diagnostic (PGD) kits and DNA methylation detection assays used in IVF embryo screening and selection. The company positions itself as a trusted partner for assisted reproductive technology (ART) providers, offering molecular diagnostic solutions that help improve fertility outcomes by enabling genomic profiling of embryos prior to implantation. Spectrum Fertility Genomics maintains strategic partnerships with international life science companies and actively participates in professional conferences including the American Society for Reproductive Medicine (ASRM) and the Preimplantation Genetic Diagnosis International Society (PGDIS), indicating alignment with clinical and regulatory standards in the reproductive medicine field.

Hamilton Thorne is a leading manufacturer of precision laser systems, CASA (Computer Assisted Sperm Analysis) systems, imaging systems, consumables, and services for assisted reproductive technology (ART) and developmental biology research. For over 30 years, the company has served IVF clinics, fertility centers, animal breeding operations, pharmaceutical companies, and research laboratories worldwide. Core products include sperm analyzers that measure motility and morphology; AI-enabled laser systems for embryo manipulation and selection; the Oosight Imaging System for oocyte assessment; micropipettes for micromanipulation; embryo culture media; and ancillary lab equipment including air purification systems, incubators, and IVF workstations. Hamilton Thorne's solutions support human fertility treatment, animal reproduction (equine, poultry, livestock), and research applications in toxicology, drug safety, and stem cell development. Manufacturing is ISO-certified and conducted in-house in the USA.

Pramand LLC develops implantable medical devices using proprietary hydrogel technology to address unmet clinical needs across surgical interventions. The company focuses on creating hydrogel-based solutions that improve patient outcomes while reducing therapy costs. Pramand's portfolio includes three primary product lines: a hydrogel implant for minimizing intrauterine adhesions (IUAs) in gynecological procedures, a dural sealant for watertight dural closure following craniotomy in neurosurgery, and a hemostatic sealant patch for controlling moderate surgical bleeding. The company operates through a business model of self-funding preclinical development with financial partners supporting clinical development and commercialization. Pramand's leadership team has successfully launched over ten hydrogel-based medical device companies that have generated over $4 billion in value and exits, collectively serving over 5 million patients worldwide. The company's proprietary hydrogel platform positions it as a specialized developer in the implantable device sector, with particular expertise in surgical sealants and hemostatic applications.

A.M.I. (Agency for Medical Innovations GmbH) is an Austrian medical device manufacturer specializing in innovative surgical solutions for Coloproctology, Urology, and Urogynecology. The company develops and manufactures minimally invasive surgical instruments and implantable devices designed to reduce patient pain, discomfort, and surgical complications while enhancing treatment outcomes. Primary product lines include the HAL-RAR system for hemorrhoid treatment, the ATOMS artificial urinary sphincter for stress urinary incontinence, incontinence slings (TVA/TOA) with post-operative adjustability, pelvic floor reconstruction meshes (HexaPro, BSC, inGYNious, CR-Mesh), the Soft Anal Band for fecal continence restoration, and the i-Stitch instrument for minimally invasive prolapse fixation. The company collaborates with internationally recognized surgeons and experts to ensure clinical validation and product refinement. A.M.I. markets its products globally to hospitals and surgical centers, with particular strength in European markets. The company maintains quality and safety standards through international certification and regulatory compliance. Manufacturing and distribution operations are based in Feldkirch, Austria.

KYRA Medical, Inc. is a Massachusetts-based medical device manufacturer specializing in innovative patient positioning products for operating rooms. Founded in 2016, the company has developed a comprehensive portfolio of patented surgical positioning solutions designed to enhance surgical safety, minimize infection risk, and prevent nerve and tissue damage. Core products include lithotomy stirrups (Classic and Comfort lines), spine positioning frames (Curve and Connect systems), surgical armboards, and operating table accessories. Known for their signature purple stirrups, KYRA's solutions serve multiple surgical specialties including urology, gynecology, orthopedics, and spine surgery. The company holds over 30 patents and collaborates with 30+ OEM partners globally. With two global headquarters and five international service centers across five continents, KYRA delivers clinician-focused positioning innovations that standardize and simplify patient setup across diverse surgical procedures.

Interscope, Inc. is a medical device manufacturer specializing in minimally invasive interventional endoscopic solutions for gastroenterology and pulmonology. The company's flagship product is the EndoRotor® System, an innovative powered endoscopic device designed for tissue resection, debridement, and removal in the gastrointestinal tract. The EndoRotor® addresses critical clinical needs including endoscopic necrosectomy, management of walled-off pancreatic necrosis (WOPN), incomplete lesion resection, post-EMR scarred lesions, Barrett's esophagus treatment, and difficult-to-reach polyp removal. The device functions as a 3-in-1 tool enabling simultaneous dissection, resection, and tissue collection. With FDA 510(k) clearance for Endoscopic Powered Resection (EPR) and FDA De Novo approval for Powered Endoscopic Debridement (PED), the EndoRotor® is distributed directly in the U.S. market. Interscope collaborates with leading academic medical centers including Duke University Medical Center, Mayo Clinic, and the Arizona Center for Digestive Health to validate clinical efficacy and procedural outcomes.